Use of Imatinib Mesylate in the Management of Chronic Myeloid Le ukaemia

Authors

  • SM Kamal Associate Professor, Department of Medicine , Khulna Medical College,Khulna
  • MA Ahad Associate Professor, Department of Gastroenterology, Khulna Medical College, Khulna
  • I Mahmood Associate Professor, Department of Medicine, Rajshahi Medical College,Rajshahi

DOI:

https://doi.org/10.3329/taj.v22i2.37752

Abstract

lmatinib mesylate (Enliven) is a synthetic tyrosine kinase inhibitor. If inhibits the break point cluster region (BCR)-Abelson (ASL) fusion protein that results from the chromosome abnormality known as the Philadelphia chromosome which  leads  to  increased cell  proliferation in chronic myeloid leukaemia (CML). lmatinib is approved for the treatment of Philadelphia chromosome positive (Ph+ ) chronic myeloid leukaemia (CML). Response is good with high 5 years survival rate. It is well tolerated. lmatinib is also recommended for the treatment of Gastro­ intestinal stromal tumour (GIST), Philadelphia positive acute lymphoblastic leukaemia (ALL) and nephrogenic systemic fibrosis (NSF). Use of imatinib in CML is discussed in this review article.

TAJ 2009; 22(1): 315-318

Downloads

Download data is not yet available.
Abstract
519
PDF
451

Downloads

Published

2009-12-01

How to Cite

Kamal, S., Ahad, M., & Mahmood, I. (2009). Use of Imatinib Mesylate in the Management of Chronic Myeloid Le ukaemia. TAJ: Journal of Teachers Association, 22(2), 315–318. https://doi.org/10.3329/taj.v22i2.37752

Issue

Vol. 22 No. 2 (2009)

Section

Review Articles